Prolonged glucocorticoid exposure in patients with RA was associated with a lower likelihood of achieving a good response to anti-TNF and anti-IL-6 therapies, relatively better-preserved effectiveness of JAK inhibitors and rituximab, and an increased rate of metabolic and skeletal complications. Here, IL6 is linked to rheumatoid arthritis.